GlassScriptPhysician profile
Charles Yen
NPI 1215930268
$51,834.20
in general payments reported to CMS, 2019-2025
100 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,203 · 2020: $2,153 · 2021: $6,860 · 2022: $5,318 · 2023: $7,583 · 2024: $10K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Consulting Fee: $9,598 · Education: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,940.18 |
| Consulting Fee | $9,597.50 |
| Education | $762.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,109.28 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Karyopharm Therapeutics INC. | $5,785.01 | 2020-2025 | Xpovio |
| Janssen Biotech, INC. | $3,718.18 | 2019-2025 | Darzalex, Erleada, Talvey |
| E.R. Squibb & Sons, L.L.C. | $3,551.19 | 2019-2025 | Opdivo, Abecma, Opdualag |
| Janssen Scientific Affairs, LLC | $3,245.96 | 2019-2025 | Tecvayli, Darzalex |
| Celgene Corporation | $2,150.43 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $2,136.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,723.81 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $1,636.27 | 2019-2025 | |
| Amgen INC. | $1,481.87 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Genzyme Corporation | $1,254.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,209.01 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $1,104.33 | 2019-2025 | Xtandi, Padcev, Xospata |
| Daiichi Sankyo INC. | $1,063.44 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $929.85 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
Show all 100 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $929.15 | 2019-2025 | |
| Incyte Corporation | $754.62 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Seagen INC. | $711.99 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Gilead Sciences, INC. | $708.40 | 2019-2025 | Trodelvy |
| Abbvie INC. | $646.60 | 2020-2025 | Venclexta |
| Lilly USA, LLC | $637.80 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $559.78 | 2022-2025 | |
| Genentech USA, INC. | $543.69 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Pharmaessentia USA Corporation | $519.99 | 2022-2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $435.22 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Taiho Oncology, INC. | $388.19 | 2020-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $378.34 | 2019-2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $324.47 | 2020-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $320.42 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.70 | 2019-2025 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $312.31 | 2019-2025 | Libtayo, Lynozyfic |
| Tersera Therapeutics LLC | $273.04 | 2023-2025 | Zoladex, Xermelo, Quzyttir |
| Stemline Therapeutics INC. | $267.52 | 2023-2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $266.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.97 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $242.36 | 2022-2023 | Myrisk |
| Aveo Pharmaceuticals, INC. | $241.99 | 2022-2024 | Fotivda |
| Array Biopharma INC | $240.21 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Kite Pharma, INC. | $235.24 | 2020-2025 | Yescarta |
| Blueprint Medicines Corporation | $220.49 | 2023-2025 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $181.60 | 2020-2023 | Monoferric |
| Tempus Ai, INC | $174.84 | 2024-2025 | Xt Cdx |
| Dendreon Pharmaceuticals LLC | $169.05 | 2022-2025 | Provenge |
| Agios Pharmaceuticals, INC. | $144.86 | 2019-2025 | Pyrukynd |
| Morphosys, US INC. | $141.16 | 2021-2024 | Monjuvi |
| Adaptive Biotechnologies Corporation | $132.29 | 2021-2025 | Clonoseq |
| Puma Biotechnology, INC. | $130.04 | 2022-2025 | |
| Astrazeneca Uk Limited | $121.99 | 2025 | Calquence |
| Verastem, INC. | $121.42 | 2019 | |
| Coherus Oncology, INC. | $119.10 | 2021 | |
| Emd Serono, INC. | $106.65 | 2019-2025 | Tepmetko, Bavencio |
| Pharming Healthcare, INC. | $105.71 | 2022-2025 | Ruconest |
| Janssen Pharmaceuticals, INC | $104.73 | 2019-2025 | |
| Cti Biopharma Corp. | $104.25 | 2022-2023 | Vonjo |
| Legend Biotech USA INC. | $101.05 | 2025 | Carvykti |
| Dova Pharmaceuticals | $100.89 | 2019-2021 | |
| Comsort, INC | $100.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $96.29 | 2022-2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $90.84 | 2021-2022 | |
| Mirati Therapeutics, INC. | $90.16 | 2023-2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $74.62 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Octapharma USA, INC. | $66.49 | 2020 | |
| Springworks Therapeutics, INC. | $64.74 | 2024 | Ogsiveo |
| Global Blood Therapeutics, INC. | $63.99 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $63.97 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $59.22 | 2024-2025 | Alymsys, Avastin, Neupogen |
| Recordati_rare_diseases_inc. | $48.27 | 2025 | Enjaymo, Sylvant |
| Alnylam Pharmaceuticals INC. | $47.97 | 2025 | Givlaari |
| Beone Medicines USA, INC. | $47.05 | 2025 | Tevimbra, Brukinsa |
| Clovis Oncology, INC. | $44.71 | 2019-2020 | |
| Boston Scientific Corporation | $44.64 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| G1 Therapeutics, INC. | $44.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $40.76 | 2019 | |
| Sumitomo Pharma America, INC. | $40.69 | 2023-2025 | Orgovyx |
| Adc Therapeutics America, INC. | $39.68 | 2023-2024 | |
| Genentech, INC. | $38.35 | 2022 | |
| Immunocore Limited | $37.29 | 2023-2024 | Kimmtrak |
| Epizyme, INC. | $35.45 | 2021 | |
| Myovant Sciences INC. | $34.10 | 2021-2022 | |
| Iovance Biotherapeutics, INC. | $33.25 | 2025 | Amtagvi |
| Sirtex Medical INC | $32.30 | 2024 | Sir-Spheres Microspheres |
| Novo Nordisk INC | $31.03 | 2023-2024 | Novoeight, Novoseven, Rebinyn |
| Foundation Medicine, INC. | $29.49 | 2019 | |
| Geron Corporation | $27.94 | 2025 | Rytelo |
| Aurobindo Pharma USA, INC. | $24.17 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.86 | 2025 | Danziten |
| Nestle Healthcare Nutrition INC. | $20.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.68 | 2024 | Xifaxan |
| Cumberland Pharmaceuticals, INC. | $20.51 | 2025 | Sancuso |
| Emmaus Medical, INC. | $19.80 | 2023 | Endari |
| Tesaro, INC. | $19.63 | 2019 | |
| Acrotech Biopharma INC. | $18.47 | 2025 | Beleodaq |
| Mylan Institutional INC. | $18.27 | 2023 | Ogivri, Fulphila |
| Fortovia Therapeutics, INC. | $18.14 | 2019 | |
| Immunogen, INC. | $18.08 | 2024 | Elahere |
| Lexicon Pharmaceuticals, INC. | $17.73 | 2020 | |
| Spectrum Pharmaceuticals INC. | $17.49 | 2024 | Rolvedon |
| Helsinn Therapeutics (U.S.), INC. | $17.45 | 2022 | |
| Novocure INC. | $17.45 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
Xpovio $5,815Calquence $1,612Darzalex $999Enhertu $957Lenvima $708Opdivo $695Imbruvica $573Erleada $562Ojjaara $551Xtandi $530Keytruda $498Besremi $492Sarclisa $487Lynparza $455Tagrisso $448Venclexta $405Jaypirca $392Ibrance $390Kisqali $388Reblozyl $367Tukysa $353Padcev $326Verzenio $303Adcetris $301Vonjo $299Lonsurf $293Inqovi $293Carvykti $292Pomalyst $287Tecvayli $277Enjaymo $273Talvey $272Orserdu $268Scemblix $267Elrexfio $265Rybrevant $263Ayvakit $247Onivyde $245Epkinly $239Libtayo $230Talzenna $229Jakafi $224Trodelvy $223Retevmo $222Orgovyx $216Inlyta $211Rezlidhia $187Tavalisse $187Monjuvi $184Braftovi $173Mektovi $173Doptelet $172Zoladex $171Ninlaro $166Stivarga $161Comirnaty $150Myrisk $149Zejula $148Jemperli $148Welireg $148Imfinzi $144Bosulif $142Gavreto $142Akeega $140Vitrakvi $139Paxlovid $138Provenge $138Fabhalta $135Alunbrig $129Opdualag $126Xt Cdx $121Iclusig $121Brukinsa $117Monoferric $112Bavencio $104Tabrecta $101Lorbrena $98.74Kyprolis $98.34Cablivi $96.45Yescarta $96.23Polivy $93.70Lunsumio $93.70Injectafer $91.64Krazati $90.16Phesgo $88.07Piqray $85.45Fotivda $83.09Ultomiris $81.76Nubeqa $77.12Qinlock $74.62Columvi $74.53Clonoseq $73.60Ruconest $73.50Elahere $69.69Ogsiveo $64.74Zepzelca $63.97Blincyto $59.99Xermelo $54.89Blenrep $53.52Lumakras $50.79
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Yen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.